focus
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: Biotech execs pursue obesity drug boom: ‘It’s the early innings’
Next article: Biotech execs pursue obesity drug boom: ‘It’s the early innings’
leisure time
leisure time
-
The (many) problems with a new study criticizing cancer screening
2025-09-03 03:18 -
'Make People Better': The CRISPR babies story you probably don't know
2025-09-03 02:55 -
Humana sues Biden admin over Medicare Advantage audit rule
2025-09-03 02:17 -
Snackable artificial intelligence, expert AI, and the pharma industry
2025-09-03 01:34 -
Stem cell treatment guidelines are released by FDA
2025-09-03 01:29 -
What to know about OceanGate, the company behind the missing Titanic submersible
2025-09-03 00:58